Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL
Patients were randomly assigned (1:1) to receive either 6 cycles of FCR every 28 days or IR for up to 6 years.
Chronic Lymphocytic Leukemia
Zanubrutinib Improves PFS, But May Not Improve OS, in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Researchers sought to determine whether zanubrutinib would improve survival in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Acalabrutinib May Reduce Toxicity in Chronic Lymphocytic Leukemia Compared With Ibrutinib
Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.
Umbralisib Plus Ublituximab Improved PFS vs Chemoimmunotherapy in CLL
The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.
Fixed Duration Ibrutinib-Venetoclax for CLL Resulted in High Rate of Undetectable MRD
Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.
Sustained CLL Response Seen With Ibrutinib Plus Venetoclax After MRD Negativity
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.
Treatment of Hypogammaglobulinemia After CAR-T Lacks Standardization
Hypogammaglobulinemia often occurs in patients with chronic lymphocytic leukemia who receive CAR-T, but there is no standard way to manage it.
Venclexta Labeling Updated With Minimal Residual Disease Negativity Data
MRD-negativity is defined as <1 CLL cell per 10,000 lymphocytes detected in the blood or bone marrow using sensitive analytical models.
